{"id":5977,"date":"2018-04-24T16:17:38","date_gmt":"2018-04-24T15:17:38","guid":{"rendered":"http:\/\/backup.altanalaw.com\/?p=5977"},"modified":"2018-11-23T10:26:15","modified_gmt":"2018-11-23T09:26:15","slug":"altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex","status":"publish","type":"post","link":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex","title":{"rendered":"Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group."},"content":{"rendered":"<p>Paris, April 24, 2018<\/p>\n<p>Altana advised all of the shareholders of the French companies Biofides and A.R.C. Pharma as part of the sale of the totality of\u00a0 share capital and the voting rights of Biofides and A.R.C. Pharma to Pharmalex France, subsidiary of the German company Pharmalex GmbH.<\/p>\n<p>Biofides is the parent company of A.R.C. Pharma, a consulting, information and assistance company who has specialized in pharmaceutical regulatory affairs for over 30 years.<\/p>\n<p>Pharmalex is a global leader in regulatory affairs consulting, in quality management, compliance and\u00a0 pharmacovigilance as well as in business development for the pharmaceutical industry.<\/p>\n<p>Altana represented the sellers, namely the majority shareholder and his children on one part and the minority shareholder operations managers on the other part.<\/p>\n<p>For the German acquirer, financed by Auctus Capital Partners AG and present on every continent, this transaction is part of a build-up strategy and extension in terms of geographic coverage.<\/p>\n<p>The management of the French entity will be entrusted to Sophie Guillaume, who already represented Pharmalex in France prior to this key acquisition for the group.<\/p>\n<p>Through this transaction, Altana once again demonstrates the firm&#8217;s expertise in the life sciences domain and its strong position on cross-border transactions.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-5978\" src=\"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg\" alt=\"\" width=\"650\" height=\"321\" srcset=\"https:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg 300w, https:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-600x296.jpg 600w, https:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG.jpg 699w\" sizes=\"(max-width: 650px) 100vw, 650px\" \/><\/p>\n<p><strong>Consel of the shareholders of Biofides and A.R.C. Pharma<\/strong><\/p>\n<p>Altana,\u00a0with Jean-Nicolas Soret (Partner) and Vincent Guilaine.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Counsel of Pharmalex France<\/strong><\/p>\n<p>R\u00f6dl, with Anne-Sophie H\u00e9bras for the legal aspectsa and Maximilian Egger for the financial aspects.<\/p>","protected":false},"excerpt":{"rendered":"<p>Paris, April 24, 2018 Altana advised all of the shareholders of the French companies Biofides and A.R.C. Pharma as part of the sale of the totality of\u00a0 share capital and the voting rights of Biofides and A.R.C. Pharma to Pharmalex France, subsidiary of the German company Pharmalex GmbH. Biofides is the parent company of A.R.C. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[125],"class_list":["post-5977","post","type-post","status-publish","format-standard","hentry","category-medias","tag-communique","expertise-droit-societes-fusions-acquisitions","avocat-jean-nicolas-soret"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group. - Advant Altana<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:fr]Altana conseille les actionnaires de Biofides et A.R.C. Pharma dans le cadre de leur cession au groupe Pharmalex[:en]Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group.[:] - Advant Altana\" \/>\n<meta property=\"og:description\" content=\"Paris, April 24, 2018 Altana advised all of the shareholders of the French companies Biofides and A.R.C. Pharma as part of the sale of the totality of\u00a0 share capital and the voting rights of Biofides and A.R.C. Pharma to Pharmalex France, subsidiary of the German company Pharmalex GmbH. Biofides is the parent company of A.R.C. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex\" \/>\n<meta property=\"og:site_name\" content=\"Advant Altana\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-24T15:17:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-11-23T09:26:15+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg\" \/>\n<meta name=\"author\" content=\"Altana Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Altana Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex\",\"url\":\"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex\",\"name\":\"[:fr]Altana conseille les actionnaires de Biofides et A.R.C. Pharma dans le cadre de leur cession au groupe Pharmalex[:en]Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group.[:] - Advant Altana\",\"isPartOf\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex#primaryimage\"},\"image\":{\"@id\":\"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex#primaryimage\"},\"thumbnailUrl\":\"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg\",\"datePublished\":\"2018-04-24T15:17:38+00:00\",\"dateModified\":\"2018-11-23T09:26:15+00:00\",\"author\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex#primaryimage\",\"url\":\"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg\",\"contentUrl\":\"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/backup.altanalaw.com\/#website\",\"url\":\"https:\/\/backup.altanalaw.com\/\",\"name\":\"Advant Altana\",\"description\":\"Soci\u00e9t\u00e9 d&#039;avocats \u00e0 la Cour de Paris\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/backup.altanalaw.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\",\"name\":\"Altana Communication\",\"url\":\"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:fr]Altana conseille les actionnaires de Biofides et A.R.C. Pharma dans le cadre de leur cession au groupe Pharmalex[:en]Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group.[:] - Advant Altana","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"[:fr]Altana conseille les actionnaires de Biofides et A.R.C. Pharma dans le cadre de leur cession au groupe Pharmalex[:en]Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group.[:] - Advant Altana","og_description":"Paris, April 24, 2018 Altana advised all of the shareholders of the French companies Biofides and A.R.C. Pharma as part of the sale of the totality of\u00a0 share capital and the voting rights of Biofides and A.R.C. Pharma to Pharmalex France, subsidiary of the German company Pharmalex GmbH. Biofides is the parent company of A.R.C. [&hellip;]","og_url":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex","og_site_name":"Advant Altana","article_published_time":"2018-04-24T15:17:38+00:00","article_modified_time":"2018-11-23T09:26:15+00:00","og_image":[{"url":"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg"}],"author":"Altana Communication","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Altana Communication","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex","url":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex","name":"[:fr]Altana conseille les actionnaires de Biofides et A.R.C. Pharma dans le cadre de leur cession au groupe Pharmalex[:en]Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group.[:] - Advant Altana","isPartOf":{"@id":"https:\/\/backup.altanalaw.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex#primaryimage"},"image":{"@id":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex#primaryimage"},"thumbnailUrl":"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg","datePublished":"2018-04-24T15:17:38+00:00","dateModified":"2018-11-23T09:26:15+00:00","author":{"@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-les-actionnaires-de-biofides-et-a-r-c-pharma-dans-le-cadre-de-leur-cession-au-groupe-pharmalex#primaryimage","url":"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg","contentUrl":"http:\/\/backup.altanalaw.com\/wp-content\/uploads\/2018\/04\/JNS-VG-300x148.jpg"},{"@type":"WebSite","@id":"https:\/\/backup.altanalaw.com\/#website","url":"https:\/\/backup.altanalaw.com\/","name":"Advant Altana","description":"Soci\u00e9t\u00e9 d&#039;avocats \u00e0 la Cour de Paris","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/backup.altanalaw.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6","name":"Altana Communication","url":"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm"}]}},"_links":{"self":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/5977"}],"collection":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/comments?post=5977"}],"version-history":[{"count":5,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/5977\/revisions"}],"predecessor-version":[{"id":6076,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/5977\/revisions\/6076"}],"wp:attachment":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/media?parent=5977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/categories?post=5977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/tags?post=5977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}